Novavax Inc. (NVAX, Financial) saw its stock price plummet by 5.02%, trading at $8.04 per share. The trading volume reached 3.81 million shares with a turnover rate of 2.38% and a price fluctuation of 6.18%.
Recent financial results indicate the company reported revenue of $84.51 million, a net loss of $121 million, and an earnings per share (EPS) of -$0.76. The gross profit was $25.69 million, with a price-to-earnings (P/E) ratio of -3.56.
Among six rating agencies, the stock received mixed reviews: 50% recommended buying, 33% advised holding, and 17% suggested selling the stock.
In the broader biotechnology sector, which recorded an overall decline of 0.33%, comparable stocks like Nkgen Biotech Inc and Pulmatrix, Inc. saw notable gains, while others like Cyclacel Pharmaceuticals, Inc. and Elevai Labs, Inc. showed high activity. Stocks with significant volatility included Psyence Biomedical Ltd and Celularity Inc.
Novavax is a biotechnology company focused on developing vaccines. It works closely with its Swedish subsidiary to produce vaccines targeting both known and emerging diseases, highlighting the potential for widespread use in combating various infectious diseases.
